Mechanistic/mammalian target of rapamycin: Recent pathological aspects and inhibitors

Authors
Abdel-Maksoud, Mohammed S.El-Gamal, Mohammed I.Benhalilou, Dalia ReyaneAshraf, SandyMohammed, Shatha AbdulghaffarOh, Chang-Hyun
Issue Date
2019-03
Publisher
WILEY
Citation
MEDICINAL RESEARCH REVIEWS, v.39, no.2, pp.631 - 664
Abstract
The mechanistic/mammalian target of rapamycin (mTOR), also known as the mechanistic target of rapamycin, regulates many normal cell processes such as transcription, cell growth, and autophagy. Overstimulation of mTOR by its ligands, amino acids, sugars, and/or growth factors leads to physiological disorders, including cancer and neurodegenerative diseases. In this study, we reviewed the recent advances regarding the mechanism that involves mTOR in cancer, aging, and neurodegenerative diseases. The chemical and biological properties of recently reported small molecules that function as mTOR kinase inhibitors, including adenosine triphosphate-competitive inhibitors and dual mTOR/PI3K inhibitors, have also been reviewed. We focused on the reports published in the literature from 2012 to 2017.
Keywords
ORALLY BIOAVAILABLE INHIBITORS; LIFE-SPAN EXTENSION; MAMMALIAN TARGET; BIOLOGICAL EVALUATION; AMINO-ACID; IN-VITRO; PYRIMIDINE-DERIVATIVES; ANTITUMOR-ACTIVITY; SIGNALING PATHWAY; KINASE INHIBITOR; ORALLY BIOAVAILABLE INHIBITORS; LIFE-SPAN EXTENSION; MAMMALIAN TARGET; BIOLOGICAL EVALUATION; AMINO-ACID; IN-VITRO; PYRIMIDINE-DERIVATIVES; ANTITUMOR-ACTIVITY; SIGNALING PATHWAY; KINASE INHIBITOR; aging; anticancer; kinase inhibitors; mTOR; PI3K
ISSN
0198-6325
URI
https://pubs.kist.re.kr/handle/201004/120307
DOI
10.1002/med.21535
Appears in Collections:
KIST Article > 2019
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE